Cargando…

Proceedings: Hormones in breast cancer patients on tamoxifen.

Detalles Bibliográficos
Autores principales:	Golder, M. P., Phillips, M. E., Baum, M., Griffiths, K., Fahmy, D. R., Henk, J. M., Jones, V., Preece, P. E.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1975
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2024853/ https://www.ncbi.nlm.nih.gov/pubmed/1212370

Ejemplares similares

Tamoxifen, aminoglutethimide and danazol: effect of therapy on hormones in post-menopausal patients with breast cancer.
por: Coombes, R. C., et al.
Publicado: (1982)

Proceedings: Hormones and the prostate.
por: Griffiths, K.
Publicado: (1974)

Proceedings: Spleen size in patients with breast cancer.
por: Roberts, J. G., et al.
Publicado: (1975)

Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients
por: Ximenez, João Paulo Bianchi, et al.
Publicado: (2019)

Relation of hormones in ductal lavage fluid to age, tamoxifen treatment, and breast cancer risk
por: Chatterton, RT, et al.
Publicado: (2009)

Ovarian cysts in women receiving tamoxifen for breast cancer
por: Mourits, M J E, et al.
Publicado: (1999)

GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer
por: Mo, Zhiqiang, et al.
Publicado: (2013)

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
por: Munster, P N, et al.
Publicado: (2011)

The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer
por: Dowsett, M, et al.
Publicado: (1999)

Evaluation of tamoxifen and simvastatin as the combination therapy for the treatment of hormonal dependent breast cancer cells
por: Ibrahim, Amel B., et al.
Publicado: (2019)

Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients.
por: Lien, E. A., et al.
Publicado: (1991)

Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer
por: Braal, C. Louwrens, et al.
Publicado: (2021)

Tamoxifen--the treatment of choice. Why look for alternatives?
por: Baum, M.
Publicado: (1998)

Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours
por: MacCallum, J, et al.
Publicado: (2000)

Response of Mouse Breast Cancer Cells to Anastrozole, Tamoxifen, and the Combination
por: Xanthopoulos, J. M., et al.
Publicado: (2005)

TROP2 methylation and expression in tamoxifen-resistant breast cancer
por: Zimmers, Stephanie M., et al.
Publicado: (2018)

Long-Acting Luteinizing Hormone-Releasing Hormone Agonist for Ovarian Hyperstimulation Induced by Tamoxifen for Breast Cancer
por: Kojima, Nobue, et al.
Publicado: (2018)

Preliminary Pharmacogenomic-Based Predictive Models of Tamoxifen Response in Hormone-dependent Chilean Breast Cancer Patients
por: Miranda, Carla, et al.
Publicado: (2021)

Dual treatment of acromegaly and hormone-receptor-positive breast cancer with tamoxifen: a case report
por: Mirfakhraee, Sasan, et al.
Publicado: (2021)

Tamoxifen-Induced Epigenetic Silencing of Oestrogen-Regulated Genes in Anti-Hormone Resistant Breast Cancer
por: Stone, Andrew, et al.
Publicado: (2012)

Downregulation of miR-342 is associated with tamoxifen resistant breast tumors
por: Cittelly, Diana M, et al.
Publicado: (2010)

Modulation of transforming growth factor beta expression and induction of apoptosis by tamoxifen in ER positive and ER negative breast cancer cells.
por: Benson, J. R., et al.
Publicado: (1996)

Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: Cochrane review
por: Hind, D, et al.
Publicado: (2007)

Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer
por: Godinho, M F E, et al.
Publicado: (2010)

Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone.
por: Lissoni, P., et al.
Publicado: (1995)

Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance
por: Bekele, Raie T., et al.
Publicado: (2016)

Tamoxifen Resistance in Breast Cancer
por: Chang, Minsun
Publicado: (2012)

CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment
por: Beelen, K., et al.
Publicado: (2013)

Tamoxifen resistance and adjuvant hormone therapy
por: Howell, A
Publicado: (2005)

Resuming Sensitivity of Tamoxifen-Resistant Breast Cancer Cells to Tamoxifen by Tetrandrine
por: Wang, Yuntao, et al.
Publicado: (2021)

Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance
por: Luo, L-Y, et al.
Publicado: (2002)

Has tamoxifen had its day?
por: Baum, Michael
Publicado: (2002)

Identification of MAGEA antigens as causal players in the development of tamoxifen-resistant breast cancer
por: Wong, P-P, et al.
Publicado: (2014)

Proceedings: Immunity in patients with breast cancer.
por: Cochran, A. J., et al.
Publicado: (1975)

Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study
por: Heo, Jung-Yoon, et al.
Publicado: (2017)

Molecular prediction of tamoxifen resistance in breast cancer
por: Kok, M, et al.
Publicado: (2005)

K-ras mutation in the endometrium of tamoxifen-treated breast cancer patients, with a comparison of tamoxifen and toremifene
por: Hachisuga, T, et al.
Publicado: (2005)

Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids
por: Francini, G, et al.
Publicado: (2006)

Tamoxifen-induced ovarian hyperstimulation during premenopausal hormonal therapy for breast cancer in Japanese women
por: Yamazaki, Rena, et al.
Publicado: (2015)

Autoantibodies Specific to ERα are Involved in Tamoxifen Resistance in Hormone Receptor Positive Breast Cancer
por: Maselli, Angela, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3u3vvko2v9stf7ck859fnhcp8m